Enzon Pharmaceuticals, Inc.
ENZN
$0.06
$0.005.26%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 38.86% | -27.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 38.86% | -27.07% | |||
| Operating Income | -38.86% | 27.07% | |||
| Income Before Tax | -29.33% | 21.71% | |||
| Income Tax Expenses | 62.50% | 138.10% | |||
| Earnings from Continuing Operations | -29.98% | 16.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.98% | 16.77% | |||
| EBIT | -38.86% | 27.07% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -18.03% | 10.73% | |||
| Normalized Basic EPS | -59.09% | 37.50% | |||
| EPS Diluted | -23.00% | 2.44% | |||
| Normalized Diluted EPS | -59.09% | 37.50% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||